Serum pepsinogens can help to discriminate between H. pylori-induced and auto-immune atrophic gastritis: Results from a prospective multicenter study

Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 10.3322/caac.21660 Correa, 1988, A human model of gastric carcinogenesis, Cancer Res, 48, 3554 Correa, 1992, Human gastric carcinogenesis: a multistep and multifactorial process–First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention, Cancer Res, 52, 6735 Pimentel-Nunes, 2019, Endoscopy, 51, 365, 10.1055/a-0859-1883 Lenti, 2020, Autoimmune gastritis, Nat Rev Dis Primer, 6, 56, 10.1038/s41572-020-0187-8 Rugge, 2012, Autoimmune gastritis: histology phenotype and OLGA staging, Aliment Pharmacol Ther, 35, 1460, 10.1111/j.1365-2036.2012.05101.x Rugge, 2007, Gastritis staging in clinical practice: the OLGA staging system, Gut, 56, 631, 10.1136/gut.2006.106666 Zagari, 2017, Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti- Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis, Aliment Pharmacol Ther, 46, 657, 10.1111/apt.14248 Malfertheiner, 2017, Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report, Gut, 66, 6, 10.1136/gutjnl-2016-312288 Venerito, 2016, Oxyntic gastric atrophy in Helicobacter pylori gastritis is distinct from autoimmune gastritis, J Clin Pathol, 69, 677, 10.1136/jclinpath-2015-203405 Ogutmen Koc, 2020, Serum pepsinogen levels and OLGA/OLGIM staging in the assessment of atrophic gastritis types, Postgrad Med J Chapelle, 2020, A panel of stomach-specific biomarkers (GastroPanel®) for the diagnosis of atrophic gastritis: a prospective, multicenter study in a low gastric cancer incidence area, Helicobacter, 25, 10.1111/hel.12727 Chapelle, 2022, Serum pepsinogens combined with new biomarkers testing using chemiluminescent enzyme immunoassay for non-invasive diagnosis of atrophic gastritis: a prospective, multicenter study, Diagn Basel Switz, 12, 695 Chapelle, 2020, Long-term follow-up of gastric precancerous lesions in a low GC incidence area, Clin Transl Gastroenterol, 11, e00237, 10.14309/ctg.0000000000000237 Jeong, 2017, Distinct metaplastic and inflammatory phenotypes in autoimmune and adenocarcinoma-associated chronic atrophic gastritis, United Eur Gastroenterol J, 5, 37, 10.1177/2050640616644142 Miceli, 2015, A laboratory score in the diagnosis of autoimmune atrophic gastritis: a Prospective Study, J Clin Gastroenterol, 49, e1, 10.1097/MCG.0000000000000101 Bakulina, 2022, Non-invasive screening of autoimmune atrophic gastritis in asymptomatic subjects by serological biomarker test (GastroPanel ®), Anticancer Res, 42, 1517, 10.21873/anticanres.15624 Kishikawa, 2022, Relevance of pepsinogen, gastrin, and endoscopic atrophy in the diagnosis of autoimmune gastritis, Sci Rep, 12, 4202, 10.1038/s41598-022-07947-1 Wada, 2022, Evaluation of screening tests for autoimmune gastritis in histopathologically confirmed Japanese patients, and re-evaluation of histopathological classification, BMC Gastroenterol, 22, 179, 10.1186/s12876-022-02251-8 Leja, 2017, Multicentric randomised study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality: the GISTAR study, BMJ Open, 7, 10.1136/bmjopen-2017-016999 Zhang, 2013, Gastric parietal cell antibodies, Helicobacter Pylori infection, and chronic atrophic gastritis: evidence from a large population-based study in Germany, Cancer Epidemiol Biomarkers Prev, 22, 821, 10.1158/1055-9965.EPI-12-1343 Magris, 2020, Low pepsinogen I/II ratio and high gastrin-17 levels typify chronic atrophic autoimmune gastritis patients with gastric neuroendocrine tumors, Clin Transl Gastroenterol, 11, e00238, 10.14309/ctg.0000000000000238